Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. decreased its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 50.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,471,717 shares of the biopharmaceutical company's stock after selling 1,479,227 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.71% of Sangamo Therapeutics worth $1,275,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Meritage Portfolio Management grew its holdings in Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 6,740 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company's stock valued at $94,000 after acquiring an additional 38,850 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Sangamo Therapeutics in the 2nd quarter worth $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Sangamo Therapeutics during the second quarter worth $89,000. Finally, Golden State Equity Partners lifted its holdings in Sangamo Therapeutics by 35.2% during the third quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company's stock valued at $231,000 after purchasing an additional 69,368 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company's stock.

Analyst Ratings Changes

SGMO has been the subject of a number of research reports. Barclays boosted their target price on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an "overweight" rating in a research note on Thursday, November 14th. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Thursday, November 14th. Finally, StockNews.com lowered Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday.

Sangamo Therapeutics Price Performance

Sangamo Therapeutics stock traded down $0.00 during trading on Monday, reaching $2.01. 2,424,811 shares of the company were exchanged, compared to its average volume of 6,809,101. The stock's 50 day simple moving average is $1.69 and its two-hundred day simple moving average is $1.03. The company has a market capitalization of $419.36 million, a P/E ratio of -2.62 and a beta of 1.15. Sangamo Therapeutics, Inc. has a 52-week low of $0.30 and a 52-week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $49.41 million for the quarter, compared to analysts' expectations of $26.55 million. During the same quarter in the previous year, the company posted ($0.34) EPS. As a group, equities analysts forecast that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.